



Date: 18th November 2020
ASX Announcement (ASX: IHL)

Incannex signs corporate advisory mandate with Canary Capital

Clinical stage cannabinoid development company, Incannex Healthcare Limited (ASX: IHL, 'Incannex' or the 'Company'), is pleased to advise that it has signed a corporate advisory mandate with Canary Capital Pty Ltd ("Canary Capital"), a boutique investment management and corporate advisory firm headquartered in Sydney.

Canary Capital prides itself on creating value for its clients through long-term strategic investments in micro and small cap companies which it believes have the potential to become leaders in their field and are globally scalable. For more information, visit the Canary Capital website at: www.canarycapital.com.au.

The initial period of the engagement is 12 months until November 2021. As consideration for their services, Incannex will issue Canary Capital with 20 million unlisted options – 10 million with a strike price of \$0.15 and 10 million with a strike price of \$0.25. Both series will have an expiry date of 30 November 2023.

ENDS

The release of this announcement has been approved for issue by IHL's Board of Directors. For further details on the announcement, interested parties should contact:

Mr Joel Latham, Managing Director and Chief Executive Officer

P: +61 409 840 786

E: joel@incannex.com.au



Date: 18th November 2020
ASX Announcement (ASX: IHL)

About Incannex Healthcare Limited (ASX: IHL)

Incannex Healthcare Limited (IHL.ASX) is developing unique medicinal cannabis products for the treatment of Obstructive Sleep Apnoea (OSA), Traumatic Brain Injury (TBI)/Concussion, Acute Respiratory Distress Syndrome (ARDS) and Temporomandibular Joint Disorder (TMD). FDA registration, where being sought, is subject to clinical success.

Each indication represents major global markets and currently have no existing registered pharmacotherapy (drug) treatment, raising the possibility of patients receiving Government subsidies for products that demonstrate suitable safety and efficacy profiles in clinical trials.

There is an established body of research validating the hypothesis for the cannabinoids being used in Incannex's chosen therapeutic areas and IHL has a strong patent filing strategy (as announced "IHL files cannabinoid patent over IHL-216A for TBI" 04th October, 2019 and "IHL Files Patent over IHL-42X for OSA" 06th of December, 2019) as it develops its products in conjunction with its medical advisory board.

Further to its clinical programs, Incannex has its Australian license to import, export and distribute medicinal cannabis products and has launched a line of cannabinoid oil products. The cannabis-based oils are sold under Incannex's product supply and distribution agreement with Cannvalate Pty Ltd, which is the largest network of cannabis medicine prescribers in Australia and a major shareholder of IHL.

Website: www.incannex.com.au

Investors: investors@incannex.com.au